Data regarding the impact of hepatitis C (HCV) therapy on incidence of type 2 diabetes mellitus are limited. We used the data from the longitudinal Chronic Hepatitis Cohort Study-drawn from four large US health systems-to investigate how response to HCV treatment impacts the risk of subsequent diabetes. Among HCV patients without a history of type 2 diabetes mellitus or hepatitis B, we investi- 
Summary
Data regarding the impact of hepatitis C (HCV) therapy on incidence of type 2 diabetes mellitus are limited. We used the data from the longitudinal Chronic Hepatitis Cohort Study-drawn from four large US health systems-to investigate how response to HCV treatment impacts the risk of subsequent diabetes. Among HCV patients without a history of type 2 diabetes mellitus or hepatitis B, we investigated the incidence of type 2 diabetes from 12 weeks post-HCV treatment through December 2015. Cox proportional hazards models were used to test the effect of treatment status (sustained virologic response [SVR] or treatment failure) and baseline risk factors on the development of diabetes, considering any possible risk factor-by-SVR interactions, and death as a competing risk. Among 5127 patients with an average follow-up of 3.7 years, diabetes incidence was significantly lower among patients who achieved SVR (231/3748; 6.2%) than among patients with treatment failure (299/1379; 21.7%; adjusted hazard ratio [aHR] = 0.79; 95% CI:
0.65-0.96). Risk of diabetes was higher among African American and Asian
American patients than White patients (aHR = 1.82 and 1.75, respectively; P < .05), and among Hispanic patients than non-Hispanics (aHR = 1.86). Patients with BMI ≥ 30 and 25-30 (demonstrated higher risk of diabetes aHR = 3.62 and 1.72, respectively; P < .05) than those with BMI < 25; patients with cirrhosis at baseline had higher risk than those without cirrhosis (aHR = 1.47). Among a large US cohort of patients treated for HCV, patients who achieved SVR demonstrated a substantially
| INTRODUC TI ON
Data regarding the impact of hepatitis C (HCV) therapy on incidence of type 2 diabetes mellitus (T2D) are limited. European studies from the interferon era of HCV therapy suggested that viral suppression and clearance greatly reduce the risk of future insulin resistance and T2D. [1] [2] [3] In contrast, other studies have found no significant difference in the incidence of T2D or insulin resistance between treated and untreated HCV patients. 4, 5 There remains a lack of current data regarding the effect of HCV-related complications and treatment outcomes on the incidence of T2D in the United States, particularly among racially diverse populations.
We evaluated the impact of HCV treatment response, the presence of cirrhosis and other factors on the incidence of T2D using longitudinal data from the Chronic Hepatitis Cohort Study (CHeCS), a geographically and racially diverse cohort of over 13 000 patients from four large US health systems.
| ME THODS

| Patient population
CHeCS is an observational multicenter study that includes adult (≥18 years) chronic hepatitis C patients from four large health systems.
The study follows all guidelines of the US Department of Health and 
| Baseline covariates and possible risk factors
Baseline 
| Statistical analysis
Time-to-event outcomes included the incidence of T2D (defined using ICD9/10 codes) or death. Follow-up began after the achievement of SVR or, for treatment-failure patients, the date 12 weeks after HCV treatment initiation. Patients were followed until the outcome of interest or 10 years of follow-up. Cox proportional hazards regression was used to estimate the impact of SVR and other factors lower risk for the development of type 2 diabetes mellitus than patients with treatment failure.
K E Y W O R D S
insulin resistance, race, treatment failure, virologic suppression TA B L E 1 Association of baseline covariates with T2D incidence: univariate effects and variable by interaction with SVR ALT and cirrhosis are highly correlated, they were fitted into multivariable models separately to avoid confounding effects. 
| RE SULTS
| Effect of SVR on incidence of T2DM
After adjustment for baseline covariates, SVR reduced the risk of T2D by 21% (aHR = 0.79, 95% CI: 0.65-0.96, P = .02; Figures 1 and   2 ). There was no interaction between SVR and other risk factors,
indicating an independent effect of SVR on incidence of T2D.
F I G U R E 1 Cumulative incidence of type 2 diabetes in patients who did and did not achieve sustained virologic response (SVR)
Multivariate model of the impact of baseline covariates on the risk of type 2 diabetes
| Effect of additional risk factors on incidence of T2DM
Higher BMI was associated with higher risk of incident T2D; in patients with BMI ≥ 30, the risk of T2D was almost 4 times higher than in patients with BMI <25 (aHR = 3.6; 95% CI: 2.2-5.95; Figure 2 ). Race was also associated with the risk of T2D; African American and Asian American, American Indian, or Pacific Islander (ASINPI) patients demonstrated risks 1.82-fold and 1.75-fold higher, respectively, than the White patients. There was no significant difference in the risk for T2D
between African American and ASINPI patients. Risk increased with age. Hispanics had an almost two-fold higher risk than non-Hispanics.
Patients with baseline cirrhosis demonstrated 1.5-fold higher risk of T2D than those without cirrhosis (Figure 3 ). The sensitivity analysis showed a nonsignificant effect of ALT on T2D development (P = 0.08).
| D ISCUSS I ON
In a large US cohort of patients treated for HCV, we found that the achievement of SVR independently reduced the risk of T2D. There were no SVR-by-covariate interactions detected, meaning the SVR effect was consistent across patient demographic characteristics and clinical conditions at the time of treatment, including serum alanine aminotransferase (ALT) levels.
We observed an independent effect of HCV-related cirrhosis on increasing T2D incidence after adjusting for other covariates as well as SVR status. This effect has been reported previously; univariate analyses in a smaller European study (n = 365) showed that increasing fibrosis score was a risk factor for the development of T2D. 2 We did not observe a significant effect of ALT in either univariate or multivariate analyses. It is possible, however, that the lack of a significant finding was a consequence of a relatively large proportion (20%) of missing ALT data and/or the strong correlation between ALT and cirrhosis, which may have diminished the observed effect of ALT.
Race has been previously identified as a factor associated with increased the risk of T2D in the general US population and among patients with HCV in Europe. 9, 10 Our results are consistent with these findings, although the effects we observed were larger than those reported in other studies; the risk of T2D was 92% higher among African American patients and 75% higher among ASINPI patients compared with Whites, after adjusting for BMI and other covariates.
Some studies have suggested that sex and HCV genotype are associated with the risk of T2D, but these results have not been consistent. 9 In our study, sex was a significant risk factor in univariate analysis, but was not significant after adjusting for other covariates.
HCV genotype was not significantly associated with T2D incidence in either univariate or multivariate analyses.
F I G U R E 3 Cumulative incidence of type 2 diabetes in patients by age, BMI, cirrhosis status and hispanic ethnicity variable-by-SVR interactions and the increasing uptake of DAA treatment in the HCV patient population, we expect that our observations regarding the impact of race and cirrhosis on the development of T2D may be generalizable to a broader population of patients with HCV.
In conclusion, among a geographically and racially diverse cohort of more than 5000 patients from US healthcare systems, successful HCV treatment was associated with significant reductions in the incidence of T2D. African American and ASINPI race as well as the presence of cirrhosis appear to increase the risk of developing T2D among those without SVR. Therefore, patients with these risk factors should be monitored closely for T2D prevention and care.
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